Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years.

Fausto PetrelliAlessandro InnoAntonio GhidiniStefania GoriMelissa Bersanelli

Published in: Cancer immunology, immunotherapy : CII (2020)

We conclude that ICIs may be offered in patients older than 75 years, providing a complete geriatric and clinical evaluation is performed in all subjects before starting therapy.

Keyphrases

clinical evaluation
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
physical activity
patient reported outcomes
mesenchymal stem cells
cell therapy
bone marrow